Science & Technology
CTO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipients
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R44CA287634-01A1
Award Ceiling
$2.0M
Award Floor
$2.0M
Close Date
Aug 31, 2026
169 days leftTotal Funding
$2.0M
Expected Awards
1
Posted Date
Sep 20, 2024
Cost Sharing Required
No
Grants.gov ID
sbir-1R44CA287634-01A1
Description
SBIR Phase Phase II award: "CTO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipients" awarded to Cytoagents, Inc. in PITTSBURGH, Pennsylvania. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $1,999,990. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.